Skip to main content

Coherent Introduces 1000 mW Red Laser Modules for Super-Resolution Microscopy

Written by Customer Service on . Posted in Public Companies.

Coherent OBIS 640 XT

The OBIS 640 XT is a red laser module matching the high output power, low noise, beam quality, and compact size of Coherent’s existing blue and green laser modules, to enable high-performance super-resolution microscopy..
The OBIS 640 XT is a red laser module matching the high output power, low noise, beam quality, and compact size of Coherent’s existing blue and green laser modules, to enable high-performance super-resolution microscopy..

PITTSBURGH, Jan. 18, 2024 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE: COHR), a leader in lasers and thermoelectrics for life sciences and scientific research, today announced the introduction of the OBIS 640 XT, a diode-pumped solid-state (DPSS) laser module with up to 1000 mW output at 640 nm for super-resolution microscopy (SRM).

Coherent's OBIS 640 XT

Innovation in visible and ultraviolet lasers is enabling breakthroughs in SRM that can resolve macromolecular structures and provide crucial new insights into cell biology. Coherent introduced the OBIS 640 XT, a red laser module that matches the high output power, low noise, beam quality, and compact size of its existing portfolio of blue and green laser modules, which as a complete set enable high-performance SRM systems.

“We continue to innovate and extend our portfolio of laser modules for life sciences, which is the largest in the industry, has for many years been a market-leading flagship product for Coherent, and continues to be the benchmark in laser modules for advanced life sciences applications,” said Dr. Torsten Rauch, Senior Vice President, Solid-State Lasers Europe Business Unit. “With the OBIS 640 XT, the product portfolio will now enable advances in super-resolution microscopy, just as it has enabled flow cytometry and DNA sequencing before that.”

The portfolio of laser modules for life sciences includes the Sapphire and OBIS LS/LX/XT product lines, covering a wide range of output power and wavelengths from near-infrared to ultraviolet. The OBIS 640 XT will be generally available by the end of calendar Q1 2024.

Coherent’s broad portfolio of products for instrumentation in life sciences also includes precision optics, filters, assemblies, and thermoelectric modules. System providers can expand assembly manufacturing at Coherent’s facilities in Dallas, Texas; Fuzhou, China; and Ho Chi Minh City, Vietnam, which are certified to ISO 13485 for biomedical assemblies.

Coherent will showcase its broad range of products and innovations for sensing at Photonics West 2024 in San Francisco, Jan. 30 to Feb. 1, Booth #4805 and at BiOS Expo Jan. 27-28, part of Photonics West, in Booth #8630.

About Coherent

Coherent empowers market innovators to define the future through breakthrough technologies, from materials to systems. We deliver innovations that resonate with our customers in diversified applications for the industrial, communications, electronics, and instrumentation markets. Headquartered in Saxonburg, Pennsylvania, Coherent has research and development, manufacturing, sales, service, and distribution facilities worldwide. For more information, please visit us at coherent.com.

Contact

Mark Lourie
Vice President, Corporate Communications
corporate.communications@coherent.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8e2ef231-cfbd-40c6-81cc-1affedef244f

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.